BiotechTube
Yellowstone Biosciences

Yellowstone Biosciences

London, United Kingdom· Est.
yellowstonebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Yellowstone Biosciences is a private, preclinical-stage biotech developing novel therapies targeting common antigens in cancer. Founded in 2017 and headquartered in Oxford, UK, the company leverages pioneering academic research from Oxford University, specifically in AML, and is led by an experienced executive team with backgrounds in companies like Juno Therapeutics, Sana Biotechnology, and Immunocore. With significant backing from the FTSE 250 healthcare investor Syncona, Yellowstone is positioned to advance its platform towards identifying and validating new therapeutic targets for a range of cancers.

OncologyHematological Oncology

Technology Platform

Platform focused on identifying and therapeutically targeting a novel class of frequently expressed antigens on cancer cells, derived from pioneering research on myeloid stem cells in acute myeloid leukemia (AML).

Opportunities

The platform targets frequently expressed antigens, which could enable therapies for large patient populations within cancer indications, offering a more scalable alternative to personalized therapies.
The significant unmet need in AML, an aggressive cancer with poor survival rates, provides a clear and urgent initial clinical pathway.
Backing from Syncona provides long-term capital and strategic support to derisk the platform and pursue this substantial oncology market opportunity.

Risk Factors

The core scientific risk is validating that the targeted 'frequently expressed antigens' offer a sufficient therapeutic window to avoid damaging healthy tissues.
As a preclinical company, it faces the high attrition rates inherent in early-stage drug discovery.
The oncology field is intensely competitive, requiring Yellowstone to rapidly demonstrate a differentiated and superior approach to target discovery and therapeutic intervention.

Competitive Landscape

Yellowstone operates in the highly competitive oncology drug discovery space, competing with large pharma, biotechs, and academic centers searching for novel cancer targets and developing next-generation immunotherapies (e.g., bispecifics, CAR-T). Its differentiation lies in its specific focus on a class of common antigens derived from foundational stem cell biology in AML, and its unique combination of clinical-academic insight and seasoned biotech execution.

More companies in United Kingdom →